Inclusion Criteria:  Brain metastases of solid tumor (carcinoma of unknown origin may be included but histological verification in case of BM alone is required) Progression of previously treated lesion as decided by the multidisciplinary team conference Previous single fraction SRS in area in question and dose plans must be available electronically Previous single fraction SRS given > 3 months previously ECOG (Eastern Cooperative Oncology Group) performance status ≤2 Life expectancy >3 months Signed written consent. Patients may have more than one recurring lesion and may also have new, untreated metastases which may be treated with standard SRS (up to a total of 4 metastases in accordance with Danish national guidelines).  Exclusion Criteria:  Two previous courses of radiotherapy for the same metastasis (e.g. SRS and WBRT) Target lesions located in- or in proximity to eloquent brain areas that require reduction of radiotherapy dose Target lesion gross tumor volume (GTV) for radiotherapy greater than 14,1 cm3 (equivalent to a sphere with a diameter of 3 cm) Current or planned concomitant medical treatment that is likely to be active against brain metastases (e.g. tyrosine kinase inhibitors for EGFR-positive (epidermal growth factor receptor) non-small cell lung cancer) or that may influence interpretation of images (e.g. bevacizumab, a monoclonal antibody directed towards VEGF (vascular endothelial growth factor)) in the opinion of the investigators Contraindication to magnetic resonance imaging using Gadolinium contrast enhancement (e.g. pacemaker, metallic implant or impaired renal function) Rapid extracranial disease progression that in the opinion of the investigators confer a high risk of drop out from the study without evaluation scan at 3 months